Contents hide 1 Myelofibrosis 1.1 Initial dose 1.2 Insufficient response for patients starting treatment with a platelet count ≥100 X 10^9/L 1.2.1 Consider dose increases in patients who meet all of the following conditions: 1.3 Insufficient response for patients starting treatment with a platelet count 50 x 10^9/L to <100 x 10^9/L 1.3.1 Consider dose increases in patients who meet all of the following conditions: 2 Polycythemia Vera 2.1 Increasing dose for insufficient response 2.1.1 Consider dose increases in patients who meet all of the following criteria: 3 Acute Graft versus Host Disease 3.1 Tapering dose 4 Chronic Graft versus … Continue reading RUSODX (Ruxolitinib)